Valued at $52.9 billion by market cap, New York-based MetLife, Inc. (MET) provides various services related to insurance, annuities, employee benefits, and asset management. Its offerings includes a wide range of insurance, annuities and capital market products, with operations spanning the Americas, the Indo-Pacific and EMEA.

Companies worth $10 billion or more are commonly referred to as “large-cap stocks,” and MetLife fits the bill perfectly. Given the company’s extensive operations spread across the globe and long-standing history, its valuation above this mark is unsurprising.

MetLife touched its all-time high of $89.05 on Nov. 27, 2024 and is currently trading 11.8% below that peak. MET stock has dropped 5.4% over the past three months, lagging behind the Nasdaq Composite’s ($NASX) 4% gains during the same time frame.

MetLife has underperformed Nasdaq over the longer term as well. MET stock dropped 4.1% on a YTD basis and gained 11.7% over the past 52 weeks, lagging behind NASX’s marginal 6 bps dip in 2025 and 12.3% returns over the past year.

To confirm the recent downturn and reversal, MET stock dropped below its 200-day moving average in early April and has climbed back above its 50-day moving average in May.

MetLife’s stock prices observed a marginal uptick in the trading session after the release of its Q1 results on Apr. 30. While the company’s net investment income observed a notable drop, its premiums, fees and other revenues observed a notable boost. Its overall adjusted revenues for the quarter jumped 10.6% year-over-year to $18.8 billion, beating the Street’s expectations by 3.4%. However, its adjusted EPS for the quarter increased by a much more modest 7.1% year-over-year to $1.96, missing the consensus estimates by 1.5%.

MetLife has also underperformed its peer Aflac Incorporated’s (AFL) 1.2% dip on a YTD basis and 15.7% surge over the past 52-week period.

Nevertheless, analysts remain optimistic about the stock’s prospects. Among the 17 analysts covering the MET stock, the consensus rating is a “Strong Buy.” Its mean price target of $94.33 suggests a 20.1% upside potential from current price levels.